Evaluation of ProstAsure index in the detection of prostate cancer: A preliminary report

Urology

Volumn 51, Issue 1, 1998, Pages 132-136

  Babaian, R Joseph ^a   Fritsche, Herbert A ^b   Zhang, Zhen ^b   Zhang, K Hong ^b   Madyastha, K Rama ^b   Barnhill, Stephen D ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CREATINE KINASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASSAY; CANCER DIAGNOSIS; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AGED, 80 AND OVER; FALSE POSITIVE REACTIONS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 0031937812     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00574-8     Document Type: Article

References (17)

1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, and Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
2. Babaian RJ, Camps JL, Frangos DN, Ramirez EI, Tenney DM, Hassell JS, and Fritsche HA: Monoclonal prostate-specific antigen in untreated prostate cancer: relationship to clinical stage and grade. CA Cancer J Clin 67: 2200-2206, 1991.
3. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, and Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161, 1991.
4. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, and Cooner WH: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147(3Pt2): 815-816, 1992.
5. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, and Lieber MM: Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
6. Babaian RJ, Troncoso P, Steelhammer LC, Lloreta-Trull J, and Ramirez E: Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. J Urol 154: 1808-1812, 1995.
7. Mettlin C, Littrup PJ, Kane RA, Murphy GP, Lee F, Chesley A, Badalament R, and Mostofi FK: Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project. CA Cancer J Clin 74: 1615-1620, 1994.
8. Christensson A, Laurell CB, and Lilja H: Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755-763, 1990.
9. Lilja H, Christensson A, Dahlen U, Matikainen M, Nilsson O, Pettersson K, and Lovgren T: Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
10. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, and Alfthan O: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
11. Lilja H, Cockett ATK, and Abrahamsson PA: Prostate specific antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. CA Cancer J Clin 70(suppl): 230-234, 1992.
12. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, Abrahamsson PA, and Lilja H: Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
13. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Drawer MK, et al: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
14. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percent of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
15. Prestigiacomo AF, Lilja H, Pettersson K, Wolfert RL, and Stamey TA: A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 156: 350-354, 1996.
16. Stamey TA, Barnhill SD, Zhang Z, Madyastha KR, Prestigiacomo AF, Jones K, and Chan D: Effectiveness of PROSTASURE in detecting prostate cancer (PCa) and benign prostatic hyperplasia (BPH) in men age 50 and older (abstract). J Urol 155: 436A, 1996.
17. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.